NCT02296242: A trial that was reported late by BioMed Valley Discoveries, Inc
This trial has reported, although it was 13 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02296242 |
|---|---|
| Title | Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 30, 2014 |
| Completion date | June 15, 2017 |
| Required reporting date | June 15, 2018, midnight |
| Actual reporting date | June 28, 2018 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 13 |